The consensus, watching the obesity-drug boom, is that everyone is rushing in. On the patent record, that's true — and it's exactly why a dose of skepticism is warranted.
Here's the single fact worth pinning up: filing a multi-receptor peptide patent is, relatively speaking, the easy part. Hanmi's grant US11332508B2 on a triple glucagon/GLP-1/GIP agonist, and Zealand's US11395847B2 on dual GLP-1/GLP-2 agonists, are real, granted, and impressive. They are also not approved obesity drugs.
Acknowledge the bull case: the multi-agonist concept is validated, the science is sound, and several of these designs come from serious companies. A crowded, sophisticated filing field is a sign of a real opportunity, not a fad.
But read the gap. Between a granted composition patent and a marketed drug sit years of trials, a real chance of unacceptable side effects, manufacturing at scale, and regulatory approval. The failure rate in that gap is high. A patent proves you invented a molecule; it proves nothing about whether it helps or harms people.
The contrarian point isn't that these molecules will fail — many will, some won't, and no one can call which from the patent alone. It's that counting patents as if they were products systematically overstates how crowded the actual market will be. The filing field is dense; the eventual product field will be far thinner.
So the reality check on 2022's multi-agonist wave: read it as a map of where smart researchers placed bets, not as a forecast of competition. The patents are real. The proof — the part that turns a molecule into a medicine — is still mostly unwritten.